Proximagen Acquires CNS Research Programs From GlaxoSmithKline
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline retains the value of two CNS research programs in the U.K. by divesting them to Proximagen
You may also be interested in...
Upsher-Smith To Buy U.K. Biotech Partner Proximagen For $347 Million
Proposed acquisition mimics other recent M&A deals, like Sanofi/Genzyme, with inclusion of contingent-value rights pegged to success of two clinical candidates.
Lundbeck Invests £10M In CNS-Focused Proximagen
Lundbeck's support for Proximagen comes as biotechs struggle for survival in the high-risk CNS space.
Lundbeck Invests £10M In CNS-Focused Proximagen
Lundbeck's support for Proximagen comes as biotechs struggle for survival in the high-risk CNS space.